These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22547409)

  • 1. Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers.
    Wald NJ; Bestwick JP; George LM; Wu T; Morris JK
    J Med Screen; 2012 Jun; 19(2):60-7. PubMed ID: 22547409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.
    De Vivo A; Baviera G; Giordano D; Todarello G; Corrado F; D'anna R
    Acta Obstet Gynecol Scand; 2008; 87(8):837-42. PubMed ID: 18607829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
    Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
    BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study.
    Myers JE; Kenny LC; McCowan LM; Chan EH; Dekker GA; Poston L; Simpson NA; North RA;
    BJOG; 2013 Sep; 120(10):1215-23. PubMed ID: 23906160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy.
    Parra-Cordero M; Rodrigo R; Barja P; Bosco C; Rencoret G; Sepúlveda-Martinez A; Quezada S
    Ultrasound Obstet Gynecol; 2013 May; 41(5):538-44. PubMed ID: 22807133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
    Myatt L; Clifton RG; Roberts JM; Spong CY; Wapner RJ; Thorp JM; Mercer BM; Peaceman AM; Ramin SM; Carpenter MW; Sciscione A; Tolosa JE; Saade G; Sorokin Y; Anderson GD;
    BJOG; 2013 Sep; 120(10):1183-91. PubMed ID: 23331974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.
    Wald NJ; Morris JK; Ibison J; Wu T; George LM
    Prenat Diagn; 2006 Jun; 26(6):559-64. PubMed ID: 16700087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
    Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
    Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antenatal screening for Down syndrome using serum placental growth factor with the combined, quadruple, serum integrated and integrated tests.
    Wald NJ; Bestwick JP; George LM; Huttly WJ
    PLoS One; 2012; 7(10):e46955. PubMed ID: 23056541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
    Foidart JM; Munaut C; Chantraine F; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Jun; 35(6):680-7. PubMed ID: 20205159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of pre-eclampsia by an analysis of placenta-derived cellular mRNA in the blood of pregnant women at 15-20 weeks of gestation.
    Sekizawa A; Purwosunu Y; Farina A; Shimizu H; Nakamura M; Wibowo N; Rizzo N; Okai T
    BJOG; 2010 Apr; 117(5):557-64. PubMed ID: 20121832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia.
    Wortelboer EJ; Koster MP; Cuckle HS; Stoutenbeek PH; Schielen PC; Visser GH
    BJOG; 2010 Oct; 117(11):1384-9. PubMed ID: 20840693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in antenatal screening for Down's syndrome.
    Wald NJ; Bestwick JP; Huttly WJ
    J Med Screen; 2013 Mar; 20(1):7-14. PubMed ID: 23512549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia.
    Yu J; Shixia CZ; Wu Y; Duan T
    Ultrasound Obstet Gynecol; 2011 May; 37(5):528-33. PubMed ID: 20737451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
    Savvidou MD; Noori M; Anderson JM; Hingorani AD; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Dec; 32(7):871-6. PubMed ID: 18814185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption.
    Tikkanen M; Stenman UH; Nuutila M; Paavonen J; Hiilesmaa V; Ylikorkala O
    Prenat Diagn; 2007 Dec; 27(12):1143-6. PubMed ID: 17960788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.